# Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer

> **NCT02497157** · PHASE2 · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 45 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin (L-OHP)
- **DRUG:** Irinotecan hydrochloride hydrate (CPT-11)
- **DRUG:** Continuous intravenous infusion of fluorouracil (CIV 5-FU)
- **DRUG:** Levofolinate calcium (l-LV)
- **DRUG:** Bevacizumab (Bmab)

## Key facts

- **NCT ID:** NCT02497157
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497157, "Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02497157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*